Psoriasis
Conditions
Brief summary
The primary objective of this research protocol is to assess the effect of a structured therapeutic education program on the quality of life of patients with moderate to severe psoriasis
Detailed description
Psoriasis is a chronic inflammatory skin disease affecting 1 to 3% of the French population. Moderate to severe psoriasis has a significant impact on quality of life. Psoriasis is associated with an increased risk of depression, social isolation, unemployment. In addition, it has recently be shown that patients with moderate to severe psoriasis have an increased incidence of cardiovascular risk factors such as hypertension, overweight, hyperlipidemia and exposure to tobacco and alcohol. These so-called comorbidites may have a negative impact on psoriasis management. They also may account for the reduced life expectancy reported in patients with severe psoriasis. Therapeutic education is a structured process whose objective is to help patients to acquire or to maintain competencies that are required to live with a chronic disease. Therapeutic education is an important process to be integrated into the therapeutic strategy. It has to take into account co-morbidities, social and psychological context and its priorities need to be defined with the patient.
Interventions
BEHAVIORALmultidisciplinary education program
both individual and group education sessions over a 6-month period in addition to standard psoriasis care
OTHERstandard psoriasis care alone
Sponsors
University Hospital, Toulouse
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Moderate to severe psoriasis defined as patients receiving a systemic psoriasis treatment including methotrexate, cyclosporine, PUVA, retinoids or a biological agent and with significant impact on quality of life defined as a Skindex \> 18 * Patients with palmo-plantar or erythrodermic psoriasis may be included if they can be classified as moderate to severe according the above described definitions
Exclusion criteria
* Patients not able to give informed consent, * Patients not able to follow the program, * Patients without social security affiliation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| skindex quality of life | 3 months | evaluation of quality of life |
Secondary
| Measure | Time frame |
|---|---|
| SF36 - Short Form 36 | 3 MONTHS |
| PASI - Psoriasis Area and Severity Index | 3 MONTHS |
Countries
France
Outcome results
None listed